<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="publisher-id">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2918314</article-id><article-id pub-id-type="publisher-id">IJPsy-47-30</article-id><article-id pub-id-type="doi">10.4103/0019-5545.46071</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Paper</subject></subj-group></article-categories><title-group><article-title>A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sagar</surname><given-names>K.J. Vijay</given-names></name><xref ref-type="aff" rid="AF0001">*</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Chandrashekar</surname><given-names>C.R.</given-names></name><xref ref-type="aff" rid="AF0002">**</xref></contrib></contrib-group><aff id="AF0001"><label>*</label>Assistant Professor, Department of Psychiatry, S.V. Medical College, Tirupati 517507, Tamil Nadu</aff><aff id="AF0002"><label>**</label>Professor, NIMHANS, Bangalore</aff><author-notes><corresp id="cor1"><italic>Correspondence to:</italic><bold>K.J. Vijay Sagar,</bold> Department of Psychiatry, S.V. Medical College, Tirupati 517507, Tamil Nadu e-mail: <email xlink:href="sagarjohn@indiatimes.com">sagarjohn@indiatimes.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2005</year></pub-date><volume>47</volume><issue>1</issue><fpage>30</fpage><lpage>32</lpage><permissions><copyright-statement>&#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2005</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Haloperidol is highly effective against the positive symptoms of schizophrenia, but is less effective against the negative symptoms. It also produces marked extrapyramidal symptoms. The newer atypical antipsychotics are believed to have an equal efficacy with a favourable side-effect profile.</p></sec><sec id="st2"><title>Aim:</title><p>We assessed the effects of risperidone and haloperidol in patients with schizophrenia to compare their clinical efficacy and side-effect profile.</p></sec><sec id="st3"><title>Methods:</title><p>A double-blind, randomized, prospective, comparative trial with a parallel treatment design of 6 weeks' duration was undertaken on 46 drug-naive schizophrenics to compare the efficacy and adverse effects profile of risperidone and haloperidol.</p></sec><sec id="st4"><title>Results:</title><p>The study showed no difference in the positive and negative subscale scales on the Positive and Negative Syndrome Scale (PANSS). However, risperidone was found to have an edge over haloperidol in improving the general psychopathology as well as in bringing about global improvement.</p></sec><sec id="st5"><title>Conclusion:</title><p>Of the two drugs, the adverse effect profile of risperidone is better, with less need for the use of antiparkinsonian medication.</p></sec></abstract><kwd-group><kwd>Risperidone</kwd><kwd>haloperidol</kwd><kwd>drug-naive</kwd><kwd>efficacy</kwd><kwd>adverse effects</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Approximately 50% of patients with schizophrenia do not obtain adequate relief with conventional neuroleptics.<xref ref-type="bibr" rid="CIT1">1</xref> Though haloperidol is highly effective against the hallu-cinations and delusions of schizophrenia, it is not as useful in controlling the negative symptoms. Moreover, the potent dopamine antagonism exhibited by haloperidol is associated with a high rate of occurrence of extrapyramidal symptoms (EPS). The development of a new class of antipsychotic drugs that bind both serotonin (5-hydroxytryptamine [5-HT<sub>2</sub>]) and dopamine (D2) receptors is a major advancement. In this class, risperidone favourably evokes a lower incidence of concurrent EPS.</p><p>During the past decade, a number of double-blind trials have compared the effect of risperidone with that of haloperidol to prove its supremacy along with its favourable adverse effect profile.<xref ref-type="bibr" rid="CIT2">2</xref>&#x02013;<xref ref-type="bibr" rid="CIT5">5</xref> However, certain studies showed equal efficacy.<xref ref-type="bibr" rid="CIT6">6</xref>&#x02013;<xref ref-type="bibr" rid="CIT10">10</xref> It is noteworthy that among these, only about 4 studies<xref ref-type="bibr" rid="CIT11">11</xref>&#x02013;<xref ref-type="bibr" rid="CIT14">14</xref> were on drug-naive patients and only one was a double-blind trial. Moreover, only a few studies were done on the Indian population and this prompted the author to take up this study to evaluate the comparative efficacy and tolerability of risperidone and haloperidol in the treatment of drug-naive schizophrenics.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>The sample (<italic>n</italic>=46) was selected from the outpatient department of the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore using the criteria described below.</p><sec id="sec2-1"><title>Inclusion criteria</title><p><list list-type="order"><list-item><p>The age of the subjects (males and females) was in the range of 18&#x02013;45 years.</p></list-item><list-item><p>All subjects had paranoid schizophrenia.</p></list-item><list-item><p>The subjects should not have received any antipsychotic drug.</p></list-item><list-item><p>Informed consent was taken from the patient and/or a family member.</p></list-item></list></p></sec><sec id="sec2-2"><title>Exclusion criteria</title><p>Patients with the following were excluded:</p><p><list list-type="order"><list-item><p>Co-morbid substance dependence, mood disorder, personality disorders</p></list-item><list-item><p>Evidence of organic conditions such as dementia and epilepsy.</p></list-item></list></p><p>Except for the level of education, the two groups did not differ on any of the other sociodemographic variables such as age, sex, place of origin, marital status, occupation, duration of illness and family history.</p><p>The selected patients were admitted and randomly grouped (23 each) to receive risperidone or haloperidol therapy and the investigator was kept blind to the assignment. At baseline, along with a complete psychiatric history and physical examination, assessment in both the groups was done using the Positive and Negative Syndrome Scale (PANSS)<xref ref-type="bibr" rid="CIT15">15</xref> and the Clinical Global Improvement (CGI) scale<xref ref-type="bibr" rid="CIT16">16</xref> for efficacy, and the Udvalg for Kliniske Undersogelser (UKU) side-effect rating scale for tolerability.<xref ref-type="bibr" rid="CIT17">17</xref> The initial daily doses of risperidone and haloperidol were 2 mg and 5 mg, respectively, which were subsequently increased as per the need, reaching a maximum daily dose of 8 mg for risperidone and 15 mg for haloperidol at the end-point.</p><p>The patients were assessed at weekly intervals for 6 weeks using PANSS, which was the key measure of antipsychotic efficacy. The primary measure of efficacy was the percentage of patients showing clinical improvement defined a priori as 20% reduction from the baseline in the total PANSS score at the end-point. The CGI scale was used to evaluate the overall status at week 3 and week 6.</p><p>The patients were also assessed every week till the end-point using the UKU side-effect rating scale. While no other antipsychotic treatment was allowed, EPS in both the groups were treated with the antiparkinsonian drug trihexyphenidyl, as per the need.</p><p>For analysis, parametric statistical methods such as ANOVA and <italic>t</italic> test were applied. Non-parametric statistical tests in the form of the chi-square test was also applied. For the quality of variance, Levene test was used.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-3"><title>Efficacy parameters</title><sec id="sec3-1"><title>Efficacy on PANSS</title><p>There was no difference between the two drugs in the improvement of positive and negative symptoms (<xref ref-type="table" rid="T0001">Table 1</xref>).</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Mean (&#x000b1;SD) scores on the PANSS and the CGI scale at baseline and end-point (risperidone vs haloperidol)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Risperidone (<italic>n</italic>=23)</th><th align="center" rowspan="1" colspan="1">Haloperidol (<italic>n</italic>=23)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Positive PANSS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">15.13 &#x000b1; 4.04</td><td align="center" rowspan="1" colspan="1">15.70 &#x000b1; 2.88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;End-point</td><td align="center" rowspan="1" colspan="1">6.70 &#x000b1; 2.34<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">8.17 &#x000b1; 2.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative PANSS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">17.39 &#x000b1; 4.70</td><td align="center" rowspan="1" colspan="1">15.61 &#x000b1; 5.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;End-point</td><td align="center" rowspan="1" colspan="1">10.61 &#x000b1; 3.85<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">12.00 &#x000b1; 4.09</td></tr><tr><td align="left" rowspan="1" colspan="1">General psychopathology</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">33.30 &#x000b1; 5.79</td><td align="center" rowspan="1" colspan="1">32.43 &#x000b1; 6.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;End-point</td><td align="center" rowspan="1" colspan="1">16.65 &#x000b1; 6.60<xref ref-type="table-fn" rid="T000F2">**</xref></td><td align="center" rowspan="1" colspan="1">33.13 &#x000b1; 6.08</td></tr><tr><td align="left" rowspan="1" colspan="1">CGI severity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">4.35 &#x000b1; 0.49</td><td align="center" rowspan="1" colspan="1">4.39 &#x000b1; 0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;End-point</td><td align="center" rowspan="1" colspan="1">2.83 &#x000b1; 0.49<xref ref-type="table-fn" rid="T000F2">**</xref></td><td align="center" rowspan="1" colspan="1">3.30 &#x000b1; 0.56</td></tr></tbody></table><table-wrap-foot><fn><p>PANSS: Positive and Negative Syndrome Scale; CGI: Clinical Global Improvement</p></fn><fn id="T000F1"><label>*</label><p>p&#x0003e;0.05 (not statistically significant);</p></fn><fn id="T000F2"><label>**</label><p>p&#x0003c;0.05 (statistically significant)</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-2"><title>Efficacy on the CGI Scale</title><p>Significant global improvement (p=0.05) and reduction in severity (p=0.023) were noted (<xref ref-type="table" rid="T0001">Table 1</xref>).</p></sec></sec><sec id="sec2-4"><title>Adverse effects</title><p>Application of RMANOVA showed that significant differences exist between the groups with regard to sedation, increased duration of sleep, tremor, constipation, polyuria/polydipsia and weight gain (<xref ref-type="table" rid="T0002">Table 2</xref>).</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Significant side-effects on the Udvalg for Kliniske Undersogelser (UKU) side-effect rating scale</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Between weeks</th><th align="center" colspan="3" rowspan="1">Between groups</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1"><hr/></th><th align="left" colspan="3" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Side-effects</th><th align="center" rowspan="1" colspan="1">F</th><th align="center" rowspan="1" colspan="1">df</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">F</th><th align="center" rowspan="1" colspan="1">df</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sedation</td><td align="left" rowspan="1" colspan="1">3.084</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">6.835</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased duration of sleep</td><td align="left" rowspan="1" colspan="1">2.784</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">5.989</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.0018</td></tr><tr><td align="left" rowspan="1" colspan="1">Tremor</td><td align="left" rowspan="1" colspan="1">17.498</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">5.434</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">10.463</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">9.406</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Polyuria/polydipsia</td><td align="left" rowspan="1" colspan="1">9.094</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4.982</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.031</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight gain</td><td align="left" rowspan="1" colspan="1">1.436</td><td align="left" rowspan="1" colspan="1">6,264</td><td align="left" rowspan="1" colspan="1">0.201</td><td align="left" rowspan="1" colspan="1">6.154</td><td align="left" rowspan="1" colspan="1">1,44</td><td align="left" rowspan="1" colspan="1">0.017</td></tr></tbody></table><table-wrap-foot><fn><p>df: degrees of freedom</p></fn></table-wrap-foot></table-wrap><p>Patients in both the groups needed antiparkinsonian medication (trihexyphenidyl)&#x02014;12 patients in the risperidone group and 15 patients in the haloperidol group. The average dose used was 1.39 mg for the risperidone group and 1.7 mg for the haloperidol group (<xref ref-type="table" rid="T0003">Table 3</xref>).</p><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Requirement of antiparkinsonian medication (trihexyphenidyl) (risperidone vs haloperidol)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Antiparkinsonian medication (trihexyphenidyl)</th><th align="center" rowspan="1" colspan="1">Risperidone group (<italic>n</italic>=23)</th><th align="center" rowspan="1" colspan="1">Haloperidol group (<italic>n</italic>=23)</th><th align="center" rowspan="1" colspan="1">Chisquare test</th><th align="center" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Not received</td><td align="center" rowspan="1" colspan="1">11 (47.8)</td><td align="center" rowspan="1" colspan="1">8 (34.8)</td><td align="center" rowspan="2" colspan="1">0.93</td><td align="left" rowspan="2" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Received</td><td align="center" rowspan="1" colspan="1">12 (52.2)</td><td align="center" rowspan="1" colspan="1">15 (65.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Values in parentheses are percentages.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>In this randomized, double-blind, 6-week study, though marked improvement of 56% vs 48% on the positive subscale and 39% vs 23% on the negative subscale of PANSS was recorded, for risperidone and haloperidol, respectively, there was no statistical difference between the two groups. Thus, our conclusion of equal efficacy is in concurrence with the results of others studies.<xref ref-type="bibr" rid="CIT6">6</xref><xref ref-type="bibr" rid="CIT7">7</xref><xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT10">10</xref> Better efficacy with risperidone was recorded by some authors.<xref ref-type="bibr" rid="CIT3">3</xref>&#x02013;<xref ref-type="bibr" rid="CIT5">5</xref><xref ref-type="bibr" rid="CIT11">11</xref><xref ref-type="bibr" rid="CIT12">12</xref><xref ref-type="bibr" rid="CIT18">18</xref><xref ref-type="bibr" rid="CIT19">19</xref> However, in the general psychopathology subscale of PANSS and in terms of severity and global improvement on the CGI scale, risperidone showed more efficacy than haloperidol.</p><p>The majority of studies reporting otherwise, i.e. showing better efficacy of risperidone were on patients with chronic schizophrenia where negative symptoms are said to be prominent; the patients had responded more favourably with risperidone, which is known for its hallmark effect on negative symptoms.<xref ref-type="bibr" rid="CIT3">3</xref><xref ref-type="bibr" rid="CIT4">4</xref> Some noteworthy features of these studies include large sample sizes, i.e. 1362, 523 and 183, respectively and longer duration of trial, i.e. 8,12 and 16 weeks, respectively.</p><p>As in many other studies,<xref ref-type="bibr" rid="CIT3">3</xref>&#x02013;<xref ref-type="bibr" rid="CIT5">5</xref><xref ref-type="bibr" rid="CIT12">12</xref><xref ref-type="bibr" rid="CIT20">20</xref> the present study also showed a lower incidence and severity of adverse effects. Kontaxakis <italic>et al</italic>. during their study on 17 drug-naive, first- episode schizophrenic patients showed that all the patients reached the optimal dose of risperidone before developing EPS.<xref ref-type="bibr" rid="CIT14">14</xref></p><p>The present study also evaluated the need for antiparkin-sonian medication and showed that although the risperidone group needed less therapeutic intervention, it was not statistically significant between the groups. This finding concurred with the lone multicentric study by Agarwal <italic>et al</italic>.<xref ref-type="bibr" rid="CIT21">21</xref></p><p>The merits of this study are its double-blind design, use of a flexible dosage schedule and good drug compliance. The limitations of this study include the small sample size and short duration of follow-up.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="CIT1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>JM</given-names></name></person-group><article-title>Risperidone: New horizons for the schizophrenic patient</article-title><source>J Clin Psychiatry</source><year>1994</year><volume>55</volume><fpage>5</fpage><comment>(Suppl)</comment></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borison</surname><given-names>R</given-names></name><name><surname>Pathiraja</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>B</given-names></name><etal/></person-group><article-title>Risperidone: Clinical safety and efficacy in schizophrenia</article-title><source>Psychopharmacol Bull</source><year>1992</year><volume>28</volume><fpage>213</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1381102</pub-id></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouinard</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Remington</surname><given-names>G</given-names></name><etal/></person-group><article-title>A Canadian multicentre placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients</article-title><source>J Clin Psychopharmacol</source><year>1993</year><volume>13</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7683702</pub-id></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marder</surname><given-names>SR</given-names></name><name><surname>Meibach</surname><given-names>RC</given-names></name></person-group><article-title>Risperidone in the treatment of schizophrenia</article-title><source>Am J Psychiatry</source><year>1994</year><volume>151</volume><fpage>1825</fpage><lpage>35</lpage></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peuskens</surname><given-names>J</given-names></name></person-group><article-title>Risperidone in the treatment of patients with chronic schizophrenia. A multi-national, multi-centre double-blind parallel-group study versus haloperidol. Risperidone Study Group</article-title><source>Br J Psychiatry</source><year>1995</year><volume>166</volume><fpage>712</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">7545060</pub-id></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Mesotten</surname><given-names>E</given-names></name></person-group><article-title>Risperidone versus haloperidol in the treatment of chronic psychotic patients: A multicentric, double-blind study</article-title><source>Janssen Research Foundation Clinical Research Report, RIS-BEL-7</source><year>1991</year><month>8</month></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>A</given-names></name><name><surname>Bollen</surname><given-names>K</given-names></name><name><surname>De Cuyper</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A multicentric double-blind comparative study</article-title><source>Acta Psychiatr Scand</source><year>1992</year><volume>85</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">1375801</pub-id></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoyberg</surname><given-names>OJ</given-names></name><name><surname>Fensbo</surname><given-names>C</given-names></name><name><surname>Remvig</surname><given-names>J</given-names></name><etal/></person-group><article-title>Risperidone versus perphenazine in the treatment of chronic schizophrenia in patients with acute exacerbations</article-title><source>Acta Psychiatr Scand</source><year>1993</year><volume>88</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">7508675</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>D</given-names></name><name><surname>Konitsiotis</surname><given-names>S</given-names></name><name><surname>Liskos</surname><given-names>A</given-names></name></person-group><article-title>Risperidone in the treatment of acute schizophrenic episodes</article-title><source>Eur Neuropsychopharmacol</source><year>1997</year><volume>7</volume><fpage>206</fpage><comment>(Suppl 2)</comment></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>A</given-names></name><name><surname>Gopa</surname><given-names>S</given-names></name></person-group><article-title>Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia. A randomized open trial</article-title><source>Indian J Psychiatry</source><year>2000</year><volume>42</volume><fpage>52</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21407908</pub-id></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopala</surname><given-names>LC</given-names></name><name><surname>Fredrickson</surname><given-names>D</given-names></name><name><surname>Good</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Symptoms in neuroleptic-naive, first-episode schizophrenia: Response to risperidone</article-title><source>Biol Psychiatry</source><year>1996</year><volume>39</volume><fpage>296</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8645777</pub-id></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>RA</given-names></name></person-group><article-title>Risperidone Working Group. Risperidone in the treatment of first episode psychotic patients: A double-blind multicentric study</article-title><source>Schizophr Bull</source><year>1998</year><volume>25</volume><fpage>721</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10667742</pub-id></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>BP</given-names></name><name><surname>Bhagabati</surname><given-names>D</given-names></name><name><surname>Medhi</surname><given-names>D</given-names></name></person-group><article-title>Risperidone versus haloperidol in acute and transient psychotic disorder</article-title><source>Indian J Psychiatry</source><year>2000</year><volume>42</volume><fpage>280</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21407958</pub-id></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kontaxakis</surname><given-names>VP</given-names></name><name><surname>Kontaxakis</surname><given-names>BJH</given-names></name><name><surname>Stamouli</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Optimal risperidone doses in drug-na&#x000ef;ve, first-episode schizophrenia</article-title><source>Am J Psychiatry</source><year>2000</year><volume>157</volume><fpage>7</fpage></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fisbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name></person-group><article-title>The Positive and Negative Syndrome Scale for schizophrenia</article-title><source>Schizophr Bull</source><year>1987</year><volume>13</volume><fpage>261</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">3616518</pub-id></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><source>ECDEU assessment manual for psycho-pharmacology</source><year>1976</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>US Department of HE and Welfare</publisher-name><comment>Publication No. ADM 76-338</comment></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingjaerde</surname><given-names>O</given-names></name><name><surname>Ahlfors</surname><given-names>UG</given-names></name><name><surname>Bech</surname><given-names>P</given-names></name><etal/></person-group><article-title>The UKU side effect rating scale</article-title><source>Acta Psychiatr Scand</source><year>1987</year><volume>76</volume><fpage>81</fpage><lpage>94</lpage><comment>(Suppl 334)</comment></element-citation></ref><ref id="CIT18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>O</given-names></name><name><surname>Azorin</surname><given-names>J</given-names></name><name><surname>Bouchours</surname><given-names>PH</given-names></name></person-group><article-title>Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients</article-title><source>J Clin Psychopharmacol</source><year>1996</year><volume>16</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">8834417</pub-id></element-citation></ref><ref id="CIT19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajaj</surname><given-names>P</given-names></name><name><surname>Nihalani</surname><given-names>N</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><etal/></person-group><article-title>Re-emergence of positive symptoms of schizophrenia during the course of treatment with risperidone</article-title><source>Indian J Psychiatry</source><year>1999</year><volume>41</volume><fpage>96</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21455369</pub-id></element-citation></ref><ref id="CIT20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceskova</surname><given-names>E</given-names></name><name><surname>Svetska</surname><given-names>J</given-names></name></person-group><article-title>Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses</article-title><source>Pharmacopsychiatry</source><year>1993</year><volume>26</volume><fpage>121</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7694306</pub-id></element-citation></ref><ref id="CIT21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>AK</given-names></name><name><surname>Bashyam</surname><given-names>VSP</given-names></name><name><surname>Channabasavanna</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Risperidone in Indian patients with schizophrenia</article-title><source>Indian J Psychiatry</source><year>1999</year><volume>40</volume><fpage>247</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21494480</pub-id></element-citation></ref></ref-list></back></article>